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both administered every 21 days. Clinic visits were estimated
from grade four toxicities not requiring hospitalisation. Using
the perspective of the national health care system, Spanish costs
were applied to RU data from patients who received treatment
(N = 541). Unit costs were obtained from published sources.
Mean cost per patient was calculated. RESULTS: Baseline char-
acteristics were well-balanced (72% male, 88% performance
status 0/1, 75% Stage IV). Patients received a median of four
cycles in both treatment arms. Survival was similar between arms
(HR = 0.99), with a median of about eight months. Grade 3/4
neutropenia and neutropenic fever occurred more frequently
with docetaxel (40% vs. 5%, 13% vs. 2%, respectively; p <
0.001). Most other grade 3/4 toxicities occurred at low rates
(£5%) and were similar between arms. Patients receiving doc-
etaxel were hospitalised more frequently and received more gran-
ulocyte colony-stimulating factors, erythropoietin, antibiotics
and antifungals. Patients receiving docetaxel were more likely to
incur extra clinic visits to manage grade four toxicity. Patients
treated with pemetrexed received more transfusions. Total mean
cost per patient was 309€ for pemetrexed and 1036€ for doc-
etaxel. Hospitalisation and outpatient medications accounted for
majority of costs (67% and 25% in the pemetrexed group,
respectively, and 77% and 21% in the docetaxel group, respec-
tively). CONCLUSIONS: Pemetrexed demonstrated similar efﬁ-
cacy to docetaxel in second-line treatment of NSCLC, but with
a superior toxicity proﬁle. The differences in toxicity are
expected to translate to considerable cost savings to the Spanish
health care system.
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OBJECTIVES: Health-related quality of life assessments are
increasingly used in clinical decision-making. A phase III trial of
pemetrexed versus docetaxel in second-line therapy for advanced
non-small cell lung cancer (NSCLC) showed similar efﬁcacy;
however, key safety beneﬁts were reported with pemetrexed. Fol-
lowing a pilot study in the UK (UK), an expanded study in the
UK and France was conducted to determine patient value asso-
ciated with individual toxicity proﬁles. METHODS: A discrete
choice conjoint analysis was used to quantify patient preference
and willingness-to-pay for chemotherapy. A review of trial data,
along with expert opinion, identiﬁed clinically meaningful toxi-
cities that were statistically signiﬁcantly different. Levels of risk
of: febrile neutropenia (requiring hospitalisation) and nausea,
neuropathy, arthralgia/myalgia, alopecia (all grades), were eval-
uated in the pilot. Following the pilot, arthralgia/myalgia was
removed and a sample size of 70 pre-treated NSCLC patients per
country was calculated. Patients considered unique, randomly
generated sets of 10 pair-wise choice scenarios representing levels
for toxicity attributes plus cost, designed to elicit trade-offs.
Logistic regression analysis was applied to the stated scenario
preferences against the individual attribute levels. RESULTS: In
the expanded study, patients (N = 140) were predominantly
male, mean age 61 years, and 60% Stage III, which is compara-
ble to the pilot. Pemetrexed would be accepted in preference to
docetaxel at zero cost, with a probability of 0.81 in the UK and
0.90 in France. The probability of choosing pemetrexed over
docetaxel decreases with increasing cost; however, patient pref-
erence remains strong at 0.70 in the UK and 0.85 in France with
a cost per cycle of £400 and 2500€, respectively. CONCLU-
SIONS: NSCLC patients showed clear preference for the
enhanced toxicity proﬁle with pemetrexed, which translates to
valuable quality of life gains in the second-line setting. These
data provide sensitive strength of preference measures. Addi-
tional country studies are planned.
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OBJECTIVES: To identify and describe currently available
instruments to measure patient-reported outcomes and percep-
tions of cancer-related fatigue. METHODS: A literature review
was performed in several electronic sources including the U.S.
National Cancer Institute website and the Medline database
(1966–2004) using the keywords: fatigue, asthenia, question-
naire, scale, instrument, oncology, cancer, assessment, measure,
measurement, expectation/s, relief, satisfaction, perception/s,
worry/ies. Articles located were hand-searched for further rele-
vant articles. A citation was selected for review when it referred
to the use or development of patient reported instrument(s) to
measure the impact of cancer-related fatigue or its treatment
and/or patients expectations, beliefs and concerns regarding
cancer-related fatigue. For each questionnaire located the fol-
lowing data was reviewed: instruments’ name, target population,
item number, dimensions, response scale and time frame.
RESULTS: In total, 35 citations were selected and reviewed,
which referred to 30 different instruments (27 patient-reported
outcome questionnaires –PRO’s– and 3 epidemiological survey
instruments) used to measure several aspects of cancer-related
fatigue. Questionnaires ranged from a single item to 40 items,
and the number of dimensions from 1 to 7. Almost all of the
PRO’s focused on aspects such as the intensity, frequency and
duration of fatigue, though some also measured one or more of
the following: quality of life, distress, psychological impact and
impact on motivation/activity, and barriers to patient-physician
communication. The survey instruments located were more
likely to focus on patient’s attitudes and beliefs regarding 
physician-patient interaction, psychosocial issues, accessing
information, satisfaction with fatigue management and percep-
tions of causes, among others. CONCLUSIONS: Though there
appears to be a surfeit of instruments to measure the intensity,
frequency and duration of cancer-related fatigue, and some
emphasis on the way fatigue affects quality of life there are few
instruments which incorporate other aspects such as beliefs,
expectations and attitudes which may also be useful in clinical
practice.
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OBJECTIVES: To determine the preferences of the general public
for health state descriptions of anaemia associated with cancer
treatment. The majority of patients undergoing chemotherapy
develop anaemia which leads to fatigue, and decreased quality
of life (i.e. associated with a haemoglobin under 12g/dl). Treat-
ing cancer related fatigue has not been given the importance of
